Oder Investment Management LLC Has $231,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Oder Investment Management LLC trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 2,847 shares of the biopharmaceutical company’s stock after selling 195 shares during the quarter. Oder Investment Management LLC’s holdings in Gilead Sciences were worth $231,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. Morgan Stanley increased its position in Gilead Sciences by 0.9% during the 3rd quarter. Morgan Stanley now owns 16,909,619 shares of the biopharmaceutical company’s stock worth $1,267,207,000 after purchasing an additional 158,794 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Gilead Sciences by 3.5% in the 3rd quarter. Northern Trust Corp now owns 14,922,488 shares of the biopharmaceutical company’s stock valued at $1,118,291,000 after purchasing an additional 504,475 shares during the last quarter. Pacer Advisors Inc. boosted its stake in shares of Gilead Sciences by 10.8% in the 4th quarter. Pacer Advisors Inc. now owns 5,046,652 shares of the biopharmaceutical company’s stock valued at $408,829,000 after purchasing an additional 493,920 shares during the last quarter. Van ECK Associates Corp boosted its stake in shares of Gilead Sciences by 10.1% in the 4th quarter. Van ECK Associates Corp now owns 4,992,415 shares of the biopharmaceutical company’s stock valued at $404,435,000 after purchasing an additional 457,576 shares during the last quarter. Finally, AQR Capital Management LLC boosted its stake in shares of Gilead Sciences by 12.5% in the 3rd quarter. AQR Capital Management LLC now owns 4,773,688 shares of the biopharmaceutical company’s stock valued at $357,740,000 after purchasing an additional 531,314 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on GILD. Morgan Stanley reduced their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. UBS Group reduced their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Finally, Royal Bank of Canada cut their target price on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating on the stock in a research note on Friday, April 26th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $83.69.

Gilead Sciences Stock Up 0.6 %

GILD traded up $0.37 during trading on Wednesday, hitting $65.57. 1,712,409 shares of the company’s stock were exchanged, compared to its average volume of 7,410,312. The company has a quick ratio of 0.72, a current ratio of 0.98 and a debt-to-equity ratio of 1.08. The business’s 50 day moving average is $71.03 and its two-hundred day moving average is $76.08. Gilead Sciences, Inc. has a fifty-two week low of $64.63 and a fifty-two week high of $87.86. The stock has a market cap of $81.64 billion, a P/E ratio of 181.11, a PEG ratio of 1.30 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. During the same quarter in the prior year, the company posted $1.37 earnings per share. The business’s revenue was up 5.3% on a year-over-year basis. As a group, equities analysts expect that Gilead Sciences, Inc. will post 3.79 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be issued a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.70%. Gilead Sciences’s payout ratio is 855.56%.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the sale, the insider now owns 100,936 shares in the company, valued at $7,386,496.48. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.29% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.